Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Antibody Therapeutics|August 14, 2018
Inaugural Editorial: Searching for Magic BulletsMitchell Ho
Antibody Therapeutics|June 23, 2020
Perspectives on the development of neutralizing antibodies against SARS-CoV-2Mitchell Ho
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 28, 2011
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinMitchell Ho
Frontiers in Oncology|August 21, 2019
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver CancerAarti Kolluri, Mitchell Ho
Antibody Therapeutics|October 18, 2021
Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodiesZhijian Duan, Mitchell Ho
Antibody Therapeutics|September 13, 2021
A novel IgM intranasal intervention against SARS-CoV-2Antony Yerabham, Mitchell Ho
American Journal of Physiology. Cell Physiology|September 22, 2021
Role of glypican-1 in regulating multiple cellular signaling pathwaysJiajia Pan, Mitchell Ho
Biochimica Et Biophysica Acta|July 25, 2003
Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional propertiesMitchell Ho, Mariangela Segre
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
In vitro antibody affinity maturation targeting germline hotspotsMitchell Ho, Ira Pastan
FEBS Letters|October 22, 2013
Glypican-3 antibodies: a new therapeutic target for liver cancerMingqian Feng, Mitchell Ho
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Antibody Therapeutics|August 14, 2018
Inaugural Editorial: Searching for Magic BulletsMitchell Ho
Antibody Therapeutics|June 23, 2020
Perspectives on the development of neutralizing antibodies against SARS-CoV-2Mitchell Ho
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 28, 2011
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinMitchell Ho
Frontiers in Oncology|August 21, 2019
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver CancerAarti Kolluri, Mitchell Ho
Antibody Therapeutics|October 18, 2021
Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodiesZhijian Duan, Mitchell Ho
Antibody Therapeutics|September 13, 2021
A novel IgM intranasal intervention against SARS-CoV-2Antony Yerabham, Mitchell Ho
American Journal of Physiology. Cell Physiology|September 22, 2021
Role of glypican-1 in regulating multiple cellular signaling pathwaysJiajia Pan, Mitchell Ho
Biochimica Et Biophysica Acta|July 25, 2003
Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional propertiesMitchell Ho, Mariangela Segre
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
In vitro antibody affinity maturation targeting germline hotspotsMitchell Ho, Ira Pastan
FEBS Letters|October 22, 2013
Glypican-3 antibodies: a new therapeutic target for liver cancerMingqian Feng, Mitchell Ho
Pageof 15